Coronary Stenosis Clinical Trial
— SALINEOfficial title:
Diagnostic Accuracy of the Saline-induced Distal to Aortic Coronary Pressure Ratio Compared With Clinically Available Resting and Hyperemic Indices of Coronary Artery Stenosis Severity
Verified date | May 2024 |
Source | University Hospital, Geneva |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The presence of inducible myocardial ischemia is considered as the prerequisite for the clinical benefit of coronary revascularization. In this regard, the introduction of invasive pressure-derived physiological indices to guide myocardial revascularization represented a major breakthrough for the treatment of patients with coronary artery disease (CAD), by moving the focus of coronary revascularization from anatomy to physiology . The main premise of coronary physiology is to permit determination of the functional significance of individual stenoses on a per-vessel basis, measurable at the time of clinical decision-making process, thus providing an objective marker to identify ischemic lesions, and therefore patients, most likely to benefit from coronary revascularization . Fractional flow reserve (FFR) is the most widely used pressure-derived invasive physiological index for coronary lesion assessment in contemporary clinical practice. FFR is calculated as the ratio of the mean distal coronary pressure (Pd) to the mean proximal coronary pressure (Pa) across a stenosis during maximal hyperaemia, a condition that is commonly achieved by the intracoronary or intravenous administration of a potent vasodilator agent, such as adenosine. Based on the results of landmark clinical trials, most recent guidelines recommend the use of FFR to identify hemodynamically significant coronary lesions in patients with stable CAD. Despite this, the worldwide adoption of FFR into current clinical practice remains limited , accounting for only 9.8% of coronary procedures in Switzerland . Potential reasons for the low adoption rate of coronary physiology include technical challenges and time consumption related to FFR measurements, inadequate or lack of reimbursement, physician preferences, patient-related discomfort, contraindications and costs associated with adenosine, or in certain countries, no availability of adenosine. The low use of FFR in clinical practice provided a rationale for the development of new invasive physiology indices. By negating the need for administration of pharmacologic agents such as adenosine, saving time, and reducing costs and side effects, hyperaemia-free pressure-derived physiological indices were developed to increase adoption of physiology-guided coronary revascularization into routine clinical practice.
Status | Completed |
Enrollment | 90 |
Est. completion date | January 1, 2024 |
Est. primary completion date | January 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject is =18 years of age. - Subject must be willing to sign a Patient Informed Consent (PIC). - Coronary artery disease with over 50% angiographic diameter stenosis on visual assessment, undergoing clinically indicated invasive physiological assessment by means of FFR. - Assessment of non culprit arteries with over 50% angiographic diameter stenosis on visual assessment, in patients presenting with NSTEMI. Exclusion Criteria: - Pregnant and/or breastfeeding females. - Known allergies to: heparin, contrast medium, adenosine. - Contra-indication to adenosine. - Severe renal failure (eGFR = 30 ml/min/m2). - Ostial stenosis in both the left and right coronary arteries. - Presence of a chronic total occlusion. - History of coronary artery bypass graft. - Acute coronary syndrome. - Acute myocardial infarction within the preceding two weeks. - Severe valvular heart disease. - Left main disease. - Documented left ventricular ejection fraction (LVEF) =30% as documented within maximum 6 months prior to the procedure. - Decompensated congestive heart failure. - Extreme hypotension (systolic blood pressure <100 mmHg) - Extreme bradycardia (<40 bpm). |
Country | Name | City | State |
---|---|---|---|
Switzerland | Geneva University Hospitals | Geneva |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Geneva |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Saline Pd/Pa ratio | As the patient will undergo invasive physiological assessment of an angiographic intermediate stenosis with fractional flow reserve (FFR), as per ESC guidelines recommendation (class of recommendation I, level of evidence A), we will perform measurement of saline Pd/Pa with the same pressure guidewire, requiring an additional 3-5 minutes and injection of 10 ml of saline. | during the coronarography procedure | |
Primary | Contrast Fractional Flow Reserve (FFR) | As the patient will undergo invasive physiological assessment of an angiographic intermediate stenosis with fractional flow reserve (FFR), as per ESC guidelines recommendation (class of recommendation I, level of evidence A), we will perform measurement of contrast fractional flow reserve (FFR) with the same pressure guidewire, requiring an additional 3-5 minutes and injection of 10 ml of contrast. | during the coronarography procedure | |
Primary | Adenosine Fractional Flow Reserve (FFR) | The patient will undergo invasive physiological assessment of an angiographic intermediate stenosis with fractional flow reserve (FFR), as per ESC guidelines recommendation (class of recommendation I, level of evidence A). | during the coronarography procedure | |
Primary | Resting Pd/Pa ratio | As the patient will undergo invasive physiological assessment of an angiographic intermediate stenosis with fractional flow reserve (FFR), as per ESC guidelines recommendation (class of recommendation I, level of evidence A), we will perform measurement of Pd/Pa with the same pressure guidewire, requiring an additional 3-5 minutes. | during the coronarography procedure | |
Primary | Instantaneous wave-free ratio (iFR) | The patient will undergo invasive physiological assessment of an angiographic intermediate stenosis with instantaneous wave-free ratio (iFR), as per ESC guidelines recommendation (class of recommendation I, level of evidence A). | during the coronarography procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03427996 -
Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
|
||
Terminated |
NCT03175523 -
HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Completed |
NCT01184183 -
Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy
|
||
Completed |
NCT00697372 -
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis
|
Phase 4 | |
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03054324 -
Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis
|
||
Enrolling by invitation |
NCT06194526 -
Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography
|
||
Not yet recruiting |
NCT06039748 -
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
|
||
Not yet recruiting |
NCT05753085 -
Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment
|
N/A | |
Not yet recruiting |
NCT05471687 -
Evaluation of the Functional Impact of Coronary Stenoses in Diabetics by Spectral CT
|
N/A | |
Not yet recruiting |
NCT04569669 -
The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis
|
N/A | |
Active, not recruiting |
NCT02508714 -
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
|
N/A | |
Completed |
NCT03301246 -
Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease
|
N/A | |
Completed |
NCT03606330 -
Systemic, Pancoronary and Local Coronary Vulnerability
|
||
Completed |
NCT02870140 -
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
|
N/A | |
Not yet recruiting |
NCT06071702 -
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
|
N/A | |
Completed |
NCT02275143 -
Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis
|
N/A | |
Active, not recruiting |
NCT01794065 -
The Promus Element Rewards Study
|
N/A |